J. Yang

发表

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

Edward S. Kim, A. Drilon, F. López-Ríos, 2022, BMC cancer.

Molecular identiﬁcation of an MHC-independent ligand recognized by a human (cid:1) / (cid:2) T-cell receptor

K. Hanada, Qiong J. Wang, T. Inozume, 2011 .

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

A. Shaw, S. Ou, F. de Marinis, 2019, Lung Cancer.

Jih-Hsiang Lee, H. Takami, Y. Narita, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.

R. Dziadziuszko, G. Weiss, J. Infante, 2015 .

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

L. Sequist, S. Ou, T. Mok, 2015, The Lancet. Oncology.

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

Jae Cheol Lee, Jih-Hsiang Lee, F. Siddiqui, 2017, Oncotarget.

First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

L. Sequist, K. O'Byrne, T. Mok, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.

S. Gettinger, M. Ahn, E. Felip, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.

L. Sequist, E. Smit, Gregory Riely, 2022, European journal of cancer.

MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials

P. Jänne, T. Mitsudomi, M. Ahn, 2017 .

Osimertinib as first‐line treatment for EGFR mutation‐positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts: LBA1_PR

P. Jänne, Y. Ohe, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O

M. Ahn, H. Saka, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)

H. Wakelee, E. Smit, S. Novello, 2017 .

Osimertinib as first‐line treatment for EGFR mutation‐positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts: LBA1_PR

P. Jänne, Y. Ohe, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.